LFMDP
LifeMD, Inc.
Set alert
- YTD
- -1.77%
- 1 year
- -9.75%
- Open
- 21.65
- Prev close
- 21.83
- Mkt cap
- 148.31M
- Vol
- 111
- Avg vol
- 1.64K
- EPS
- -2.26
- P/E
- 0.00
- Div yield
- 9.97%
More statistics
- Low
- 21.65
- High
- 21.65
- Forward P/E
- 0.00
- Beta
- 1.23
- Short ratio
- 0.50
- Inst. own
- 0.00%
- Dividend
- 2.22
- Ex-div date
- Oct 3, 2024
- 50-d avg
- 22.40
- 200-d avg
- 22.28
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 953.02M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -2.26
- Beta
- 1.23
- Dividend yield
- 9.97%
- Payout ratio
- 0.00%
- Profit margin
- -11.66%
- Revenue (TTM)
- 193.06M
- Revenue growth
- 38.30%
- Free cash flow
- 18.01M
- Total cash
- 37.59M
- Total debt
- 25.14M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 22.40
- 200-day average
- 22.28
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About LifeMD, Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- lifemd.com
News
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- UPDATE - LifeMD Reports Second Quarter 2026 Results
- LifeMD to Report Second Quarter 2026 Financial Results on August 5
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
- LifeMD Appoints Umesh Sripad as Chief Technology Officer
- LifeMD to Participate in Upcoming Investor Conferences
- LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
- LifeMD to Report First Quarter 2026 Financial Results on May 6
- LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
Your note
Sign in to keep a note on LFMDP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| High Income Securities Fund | 0.57% | 7,912 | 174.85K | Aug 30, 2022 |